Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation

Mennini, Natascia; Cirri, Marzia; Maestrelli, Francesca; Mura, Paola

doi:10.1016/j.ijpharm.2016.11.013

Cited by 49 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effectiveness of simultaneously exploiting the advantages of both CD and nano-lipid carriers by joining them in a unique drug delivery system, by loading the drug-CD system into the lipid nanoparticles, has recently been reported [32,33,34,35]. In particular, loading into SLN of HCT as HPβCD binary system rather than as plain drug allowed to enhance the entrapment efficiency from 57% up to 66%, to prolong the formulation stability at 4 °C from 1 to 3 months, and to improve the drug release, with an almost 3-times increase of the released amount after 6 h [21].…”

Section: Introductionmentioning

confidence: 99%

Combined Approach of Cyclodextrin Complexationand Nanostructured Lipid Carriers for the Development of a Pediatric Liquid Oral Dosage Form of Hydrochlorothiazide

et al. 2018

View full text Add to dashboard Cite

The development of specific and age-appropriate pediatric formulations is essential to assure that all children and their care-givers can easily access to safe and effective dosage forms. The need for developing specific pediatric medicinal products has been highlighted by the European Medicines Agency. The aim of this study was to investigate the effectiveness of combining the advantages of both cyclodextrin (CD) complexation and loading into nanostructured lipid carriers (NLC), to obtain a liquid oral pediatric formulation of hydrochlorothiazide (HCT), endowed with safety, dosage accuracy, good stability and therapeutic efficacy. Equimolar drug combinations as physical mixture (P.M.) or coground product (GR) with hydroxypropyl-β-cyclodextrin (HPβCD) or sulfobutylether-β-cyclodextrin (SBEβCD) were loaded into NLC, then characterized for particle size, homogeneity, Zeta potential, entrapment efficiency, gastric and storage stability. The presence of HPβCD allowed higher entrapment efficacy than NLC loaded with the plain drug, and enabled, in the case of GR systems a complete and sustained drug release, attributable to the wetting and solubilising properties of HPβCD toward HCT. In vivo studies on rats proved the superior therapeutic effectiveness of HCT-in HPβCD-in NLC formulations compared to the corresponding free HCT-loaded NLC, thus confirming the successfulness of the proposed approach in the development of an efficacious liquid oral formulation of the drug.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined Approach of Cyclodextrin Complexationand Nanostructured Lipid Carriers for the Development of a Pediatric Liquid Oral Dosage Form of Hydrochlorothiazide

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The ternary system presented improved properties, indicating its potential for enhancing safety, bioavailability, and therapeutic efficacy of NSAIDs such as oxaprozin. Mennini et al, 2016(b) [93] Oxaprozin/Rme-β-CD/Arginine…”

Section: Authors Inclusion Complex Study Design Main Findingsmentioning

confidence: 99%

Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of medicines in the treatment of inflammation, fever, and pain. However, evidence has demonstrated that these drugs can induce significant toxicity. In the search for innovative strategies to overcome NSAID-related problems, the incorporation of drugs into cyclodextrins (CDs) has demonstrated promising results. This study aims to review the impact of cyclodextrin incorporation on the biopharmaceutical and pharmacological properties of non-steroidal anti-inflammatory drugs. A systematic search for papers published between 2010 and 2020 was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and the following search terms: “Complexation”; AND “Cyclodextrin”; AND “non-steroidal anti-inflammatory drug”. A total of 24 different NSAIDs, 12 types of CDs, and 60 distinct inclusion complexes were identified, with meloxicam and β-CD appearing in most studies. The results of the present review suggest that CDs are drug delivery systems capable of improving the pharmacological and biopharmaceutical properties of non-steroidal anti-inflammatory drugs.

show abstract

“…Similar to some of the principles used in the design of multilamellar biphasic vesicles, NLCs consist of a solid lipid nanoparticle with a variable percentage of liquid lipids and surfactants included within, resulting in a disordered internal structure, and allowing increased drug loading and improved skin permeation. While many groups have been studying this delivery route [27,28,29], none are based in Canada, highlighting a potential topic of interest for groups studying topical or transdermal delivery. In particular, since the systemic delivery of insulin, vaccines, and other larger therapeutic compounds through BPVs never reached clinical stages, NLCs could present another avenue for investigation, especially as they have been primarily studied in the context of small molecule delivery.…”

Section: Chemical Permeation Enhancer-based Systemsmentioning

confidence: 99%

A Snapshot of Transdermal and Topical Drug Delivery Research in Canada

2019

View full text Add to dashboard Cite

The minimally- or non-invasive delivery of therapeutic agents through the skin has several advantages compared to other delivery routes and plays an important role in medical care routines. The development and refinement of new technologies is leading to a drastic expansion of the arsenal of drugs that can benefit from this delivery strategy and is further intensifying its impact in medicine. Within Canada, as well, a few research groups have worked on the development of state-of-the-art transdermal delivery technologies. Within this short review, we aim to provide a critical overview of the development of these technologies in the Canadian environment.

show abstract

Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation

Cited by 49 publications

References 37 publications

Combined Approach of Cyclodextrin Complexationand Nanostructured Lipid Carriers for the Development of a Pediatric Liquid Oral Dosage Form of Hydrochlorothiazide

Combined Approach of Cyclodextrin Complexationand Nanostructured Lipid Carriers for the Development of a Pediatric Liquid Oral Dosage Form of Hydrochlorothiazide

Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review

A Snapshot of Transdermal and Topical Drug Delivery Research in Canada

Contact Info

Product

Resources

About